Ligand Pharmaceuticals Incorporated (LGND) is a Healthcare stock trading at $273.81 (as of 2026-06-18), with a market capitalization of $4.65B and a trailing P/E of 30.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company developing or acquiring technologies used by pharmaceutical companies to discover and develop medicines. Its commercial products include therapies and formulations such as Kyprolis and Evomela for multiple myeloma, Veklury for COVID-19, and multiple other products including vaccines and specialty drug formulations used in areas like osteoporosis, postpartum depression, and leukemia.